DoxorubicinEconomics, PharmaceuticalEpirubicinAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideBreast NeoplasmsRazoxaneFluorouracilDrug Administration SchedulePaclitaxelTaxoidsVincristineTreatment OutcomeCisplatinAntineoplastic AgentsDose-Response Relationship, DrugChemotherapy, AdjuvantVinblastineInfusions, IntravenousGuanidineAnthracyclinesDisease-Free SurvivalDrug Resistance, NeoplasmTrimethylsilyl CompoundsGranulocyte Colony-Stimulating FactorMethotrexateSurvival AnalysisIfosfamideEtoposideNeoadjuvant TherapyDrug Resistance, MultipleDeoxycytidineP-GlycoproteinCombined Modality TherapyLiposomesSurvival RateDrug CarriersNeutropeniaTime FactorsPrednisoneAlopeciaCell Line, TumorDaunorubicinLeukopeniaDrug SynergismInjections, IntravenousNeoplasm StagingHeart DiseasesAntineoplastic Agents, PhytogenicNaphthacenesGuanidinesNeoplasm MetastasisHematologic DiseasesNauseaMitoxantroneVomitingAdministration, OralPolyethylene GlycolsDrug InteractionsSarcomaVerapamilDrug EvaluationApoptosisHeartTumor Cells, CulturedAdenocarcinoma